Crestone presents Phase 1 data from single and multiple ascending dose clinical trials with CRS3123, at the ASM Microbe Meeting in New Orleans. CRS3123 is a drug candidate in development for the treatment of C. difficile infections.
Learn More:
Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123